7月3日，开立医疗今日收盘29.46元，下跌1.50%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到253.53倍，总市值127.48亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入4.30亿元，同比-10.29%；净利润807.46万元，同 比-91.94%，销售毛利率63.19%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13开立医疗253.5389.524.08127.48亿行业平均 51.4848.994.51106.54亿行业中值36.8836.802.4850.74亿1九安医疗10.2910.400.81173.59亿2英科医疗 10.4311.240.93164.74亿3新华医疗14.5213.461.1893.06亿4奥美医疗15.4115.101.5855.66亿5山东药玻 15.4515.501.78146.13亿6振德医疗15.5914.690.9956.59亿7康德莱15.8115.821.3134.07亿8维力医疗 16.5317.181.9437.69亿9九强生物16.5815.422.0382.13亿10奥泰生物16.6717.581.3 ...

7月1日，开立医疗今日收盘30.13元，上涨1.38%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到259.29倍，总市值130.38亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.70倍，行业中值37.36倍，开立医疗排 名第119位。 股东方面，截至2025年3月31日，开立医疗股东户数14519户，较上次增加736户，户均持股市值35.28万 元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入4.30亿元，同比-10.29%；净利润807.46万元，同 比-91.94%，销售毛利率63.19%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13开立医疗259.2991.564.17130.38亿行业平均 51.7049.814.63107.66亿行业中值37.3638.092.4550.67亿1英科医疗9.9710.750.89157.50亿2九安医疗 10.2910.410.81173.68亿3新华医疗14.4113.361.1892.40亿4奥美医疗15.2814.981.5755.22亿5山东药玻 15.4615.51 ...

Company Overview - The company, Shenzhen Kaili Biomedical Technology Co., Ltd., specializes in the independent research, production, and sales of medical diagnostic and treatment equipment [1] - The main products include medical ultrasound diagnostic equipment, digestive and respiratory endoscopes, minimally invasive surgical products, and cardiovascular interventional products [1] - The company has over 20 years of experience in the ultrasound industry and is recognized as a high-tech enterprise with leading core technologies in color Doppler ultrasound [1] Financial Performance - For Q1 2025, the company reported a revenue of 430 million yuan, a year-on-year decrease of 10.29% [2] - The net profit for the same period was 8.07 million yuan, reflecting a significant year-on-year decline of 91.94% [2] - The gross profit margin stood at 63.19% [2] Market Position - The company's rolling price-to-earnings (PE) ratio is 254.73, significantly higher than the industry average of 49.45 and the median of 35.92 [2] - The total market capitalization of the company is 12.808 billion yuan [1] - Among 38 institutions holding shares, there are 35 funds, 1 brokerage, 1 social security fund, and 1 other entity, with a total holding of 52.883 million shares valued at 1.539 billion yuan [1] Competitive Landscape - The company ranks second in market share among domestic manufacturers in the ultrasound sector and tenth globally, indicating strong brand influence and competitiveness [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kaili Medical, indicating a significant decline in revenue and net profit in the first quarter of 2025 compared to the previous year [1][2] - As of June 9, 2023, Kaili Medical's stock price closed at 33.12 yuan, with a rolling PE ratio of 285.03 times, and a total market capitalization of 14.331 billion yuan [1] - The company operates in the medical device industry, specializing in the research, development, production, and sales of medical diagnostic and treatment equipment, with a strong focus on ultrasound diagnostic devices [1] Group 2 - In the first quarter of 2025, Kaili Medical reported an operating income of 430 million yuan, a year-on-year decrease of 10.29%, and a net profit of 8.0746 million yuan, down 91.94% year-on-year [2] - The company's gross profit margin stands at 63.19%, indicating a relatively high profitability despite the decline in revenue and net profit [2] - Kaili Medical ranks second among domestic manufacturers in market share for ultrasound products and tenth globally, showcasing its strong brand influence and competitiveness in the industry [1]